{
  "topic": {
    "en": "Ventricular Tachycardia (VT)",
    "zh": "心室頻脈"
  },
  "definition": {
    "en": "Ventricular tachycardia is a wide complex tachycardia (QRS ≥ 120 ms) originating from the ventricles at a rate of 100-250 bpm. It is defined as three or more consecutive ventricular beats at a rate greater than 100 beats per minute. VT is a potentially life-threatening arrhythmia and is responsible for a significant proportion of sudden cardiac deaths.",
    "zh": "心室頻脈是一種源自心室的寬 QRS 波快速心律不整（QRS ≥ 120 ms），心率為 100-250 bpm。定義為連續三個或以上的心室搏動，速率超過每分鐘 100 次。VT 是一種可能危及生命的心律不整，是猝死的重要原因之一。"
  },
  "ecg_characteristics": {
    "en": "ECG Characteristics",
    "zh": "心電圖特徵",
    "general": {
      "rate": {
        "en": "100-250 bpm",
        "zh": "100-250 bpm"
      },
      "rhythm": {
        "en": "Usually regular",
        "zh": "通常規則"
      },
      "qrs_complex": {
        "en": "Wide QRS (≥ 120 ms), morphology depends on origin",
        "zh": "QRS 波寬（≥ 120 ms），形態依起源部位而異"
      }
    }
  },
  "classification": {
    "by_duration": {
      "en": "Classification by Duration",
      "zh": "依持續時間分類",
      "types": [
        {
          "type": "nsvt",
          "name": {
            "en": "Non-Sustained VT (NSVT)",
            "zh": "非持續性心室頻脈（NSVT）"
          },
          "description": {
            "en": "Duration < 30 seconds, self-terminating. May be asymptomatic; marker of risk.",
            "zh": "持續時間 < 30 秒，可自行終止。可能無症狀；為風險標記。"
          }
        },
        {
          "type": "sustained_vt",
          "name": {
            "en": "Sustained VT",
            "zh": "持續性心室頻脈"
          },
          "description": {
            "en": "Duration ≥ 30 seconds OR requires intervention due to hemodynamic instability.",
            "zh": "持續時間 ≥ 30 秒，或因血流動力學不穩定而需介入處理。"
          }
        }
      ]
    },
    "by_morphology": {
      "en": "Classification by Morphology",
      "zh": "依形態分類",
      "types": [
        {
          "type": "monomorphic_vt",
          "name": {
            "en": "Monomorphic VT",
            "zh": "單型性心室頻脈"
          },
          "description": {
            "en": "Uniform QRS morphology. Usually reentry around scar tissue.",
            "zh": "QRS 形態一致。通常為疤痕組織周圍的折返性機轉。"
          }
        },
        {
          "type": "polymorphic_vt",
          "name": {
            "en": "Polymorphic VT",
            "zh": "多型性心室頻脈"
          },
          "description": {
            "en": "Varying QRS morphology. Often ischemia or channelopathy related.",
            "zh": "QRS 形態不一致。常與缺血或離子通道病變相關。"
          }
        },
        {
          "type": "torsades_de_pointes",
          "name": {
            "en": "Torsades de Pointes",
            "zh": "尖端扭轉型心室頻脈（Torsades de Pointes）"
          },
          "description": {
            "en": "Twisting QRS around baseline. QT prolongation-related.",
            "zh": "QRS 波繞基線扭轉。與 QT 延長相關。"
          }
        }
      ]
    }
  },
  "etiology": {
    "en": "Etiology",
    "zh": "病因",
    "structural_heart_disease": {
      "en": "Structural Heart Disease (Most Common)",
      "zh": "結構性心臟疾病（最常見）",
      "items": [
        {
          "en": "Coronary artery disease / Prior MI (Scar-related reentry)",
          "zh": "冠狀動脈疾病 / 心肌梗塞後（疤痕相關折返）"
        },
        {
          "en": "Dilated Cardiomyopathy (DCM)",
          "zh": "擴張性心肌病變（DCM）"
        },
        {
          "en": "Hypertrophic Cardiomyopathy (HCM)",
          "zh": "肥厚性心肌病變（HCM）"
        },
        {
          "en": "Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",
          "zh": "致心律失常性右心室心肌病變（ARVC）"
        }
      ]
    },
    "idiopathic_channelopathies": {
      "en": "Idiopathic / Channelopathies / Reversible",
      "zh": "原發性 / 離子通道病變 / 可逆性",
      "idiopathic_vt": {
        "en": "Idiopathic VT",
        "zh": "原發性心室頻脈",
        "items": [
          {
            "en": "RVOT VT (Right Ventricular Outflow Tract)",
            "zh": "右心室流出道心室頻脈（RVOT VT）"
          },
          {
            "en": "Fascicular VT (Left posterior fascicle most common)",
            "zh": "束支性心室頻脈（最常見為左後分支）"
          }
        ]
      },
      "channelopathies": {
        "en": "Channelopathies",
        "zh": "離子通道病變",
        "items": [
          {
            "en": "Long QT Syndrome",
            "zh": "長 QT 症候群"
          },
          {
            "en": "Brugada Syndrome",
            "zh": "布魯格達症候群"
          },
          {
            "en": "Catecholaminergic Polymorphic VT (CPVT)",
            "zh": "兒茶酚胺敏感性多型性心室頻脈（CPVT）"
          }
        ]
      },
      "reversible_causes": {
        "en": "Reversible Causes",
        "zh": "可逆性因素",
        "items": [
          {
            "en": "Electrolyte abnormalities (Hypokalemia, Hypomagnesemia, Hypocalcemia)",
            "zh": "電解質異常（低血鉀、低血鎂、低血鈣）"
          },
          {
            "en": "Drug toxicity (Digoxin, QT-prolonging agents)",
            "zh": "藥物毒性（毛地黃、QT 延長藥物）"
          },
          {
            "en": "Acute ischemia",
            "zh": "急性缺血"
          }
        ]
      }
    }
  },
  "pathophysiology": {
    "en": "Pathophysiology (Mechanisms of VT)",
    "zh": "病理生理學（VT 機轉）",
    "mechanisms": [
      {
        "type": "reentry",
        "name": {
          "en": "Reentry (Most Common)",
          "zh": "折返（最常見）"
        },
        "description": {
          "en": "Electrical signals circulate around scar or diseased tissue (post-MI, cardiomyopathy). Requires slow conduction and unidirectional block.",
          "zh": "電訊號繞著疤痕或病變組織不斷循環（心肌梗塞後、心肌病變）。需要緩慢傳導及單向阻斷。"
        }
      },
      {
        "type": "triggered_activity",
        "name": {
          "en": "Triggered Activity",
          "zh": "觸發活動"
        },
        "subtypes": [
          {
            "type": "ead",
            "name": {
              "en": "Early Afterdepolarizations (EADs)",
              "zh": "早期後去極化（EAD）"
            },
            "description": {
              "en": "Phase 2/3. Prolonged AP (Long QT). Triggers Torsades.",
              "zh": "發生於動作電位 Phase 2/3。延長的動作電位（Long QT）。觸發 Torsades。"
            }
          },
          {
            "type": "dad",
            "name": {
              "en": "Delayed Afterdepolarizations (DADs)",
              "zh": "延遲後去極化（DAD）"
            },
            "description": {
              "en": "Phase 4. Ca²⁺ overload (CPVT, digitalis toxicity). Triggers VT.",
              "zh": "發生於動作電位 Phase 4。細胞內鈣離子過多（CPVT、毛地黃中毒）。觸發 VT。"
            }
          }
        ]
      },
      {
        "type": "enhanced_automaticity",
        "name": {
          "en": "Enhanced Automaticity",
          "zh": "自動性增強"
        },
        "description": {
          "en": "Abnormal spontaneous depolarization. Seen in ischemia, electrolyte abnormalities.",
          "zh": "異常的自發去極化。見於缺血、電解質異常。"
        }
      }
    ]
  },
  "clinical_presentation": {
    "en": "Clinical Presentation",
    "zh": "臨床表現",
    "hemodynamically_stable": {
      "en": "Hemodynamically Stable",
      "zh": "血流動力學穩定",
      "symptoms": [
        {
          "en": "Palpitations",
          "zh": "心悸"
        },
        {
          "en": "Chest discomfort",
          "zh": "胸部不適"
        },
        {
          "en": "Dyspnea",
          "zh": "呼吸困難"
        },
        {
          "en": "Lightheadedness",
          "zh": "頭暈"
        }
      ]
    },
    "hemodynamically_unstable": {
      "en": "Hemodynamically Unstable",
      "zh": "血流動力學不穩定",
      "symptoms": [
        {
          "en": "Hypotension (SBP < 90 mmHg)",
          "zh": "低血壓（收縮壓 < 90 mmHg）"
        },
        {
          "en": "Altered mental status",
          "zh": "意識改變"
        },
        {
          "en": "Acute heart failure / Pulmonary edema",
          "zh": "急性心衰竭 / 肺水腫"
        },
        {
          "en": "Ischemic chest pain",
          "zh": "缺血性胸痛"
        },
        {
          "en": "Signs of shock",
          "zh": "休克徵象"
        }
      ]
    },
    "pulseless_vt": {
      "en": "Pulseless VT (Cardiac Arrest)",
      "zh": "無脈搏心室頻脈（心臟驟停）",
      "warning": {
        "en": "IMMEDIATE ACLS INTERVENTION REQUIRED",
        "zh": "需立即進行高級心臟救命術（ACLS）"
      },
      "signs": [
        {
          "en": "Unresponsive",
          "zh": "無反應"
        },
        {
          "en": "No pulse",
          "zh": "無脈搏"
        },
        {
          "en": "Apnea or agonal respirations",
          "zh": "呼吸停止或瀕死呼吸"
        }
      ]
    }
  },
  "treatment": {
    "overview": {
      "en": "Management of Ventricular Tachycardia: Acute Treatment Strategy",
      "zh": "心室頻脈處置：急性期治療策略"
    },
    "fundamental_principle": {
      "en": "Treat Wide QRS Tachycardia as VT when diagnosis is uncertain (whether VT is confirmed or not).",
      "zh": "當診斷不確定時，將寬 QRS 波快速節律當作 VT 處理（無論 VT 是否已確診）。"
    },
    "pulseless_or_unstable": {
      "en": "1. Pulseless VT or Hemodynamically Unstable",
      "zh": "1. 無脈搏 VT 或血流動力學不穩定",
      "acls_protocol": {
        "en": "Immediate ACLS Protocol",
        "zh": "緊急 ACLS 流程",
        "steps": [
          {
            "en": "Prioritize CPR for Pulseless VT",
            "zh": "無脈搏 VT 優先進行 CPR"
          },
          {
            "en": "Unsynchronized shock (Defibrillation) for Pulseless VT",
            "zh": "無脈搏 VT 使用非同步電擊（去顫）"
          },
          {
            "en": "Synchronized cardioversion for UNSTABLE VT with PULSE (Start at 100 J biphasic, escalate if needed)",
            "zh": "不穩定但有脈搏的 VT 使用同步電擊（雙相波從 100 J 開始，必要時提高能量）"
          }
        ]
      }
    },
    "stable_sustained_vt": {
      "en": "2. Stable but Sustained VT (Hemodynamically Stable with Pulse)",
      "zh": "2. 穩定但持續性 VT（血流動力學穩定且有脈搏）",
      "approach": {
        "en": "Intravenous Antiarrhythmic Therapy",
        "zh": "靜脈抗心律不整藥物治療"
      },
      "agents": [
        {
          "drug": "Amiodarone",
          "dose": {
            "en": "150 mg IV over 10 min, then 1 mg/min × 6h, then 0.5 mg/min",
            "zh": "150 mg IV 於 10 分鐘內給予，之後 1 mg/min × 6 小時，再 0.5 mg/min"
          },
          "notes": {
            "en": "First-line agent; broad spectrum; preferred especially with reduced EF",
            "zh": "第一線用藥；廣效；尤其適用於射出分率降低者"
          }
        },
        {
          "drug": "Lidocaine",
          "dose": {
            "en": "1-1.5 mg/kg bolus, then 1-4 mg/min infusion",
            "zh": "1-1.5 mg/kg 靜脈推注，之後 1-4 mg/min 持續輸注"
          },
          "notes": {
            "en": "Alternative; consider in acute ischemia/MI setting",
            "zh": "替代選擇；急性缺血/心肌梗塞時可考慮"
          }
        },
        {
          "drug": "Procainamide",
          "dose": {
            "en": "20-50 mg/min until arrhythmia suppressed, max 17 mg/kg",
            "zh": "20-50 mg/min 直到心律不整終止，最大劑量 17 mg/kg"
          },
          "notes": {
            "en": "Monitor for hypotension and QRS widening; avoid in severe HF",
            "zh": "監測低血壓及 QRS 波寬度；嚴重心衰竭時避免使用"
          }
        }
      ]
    },
    "electrical_cardioversion": {
      "en": "3. Electrical Cardioversion for Stable VT",
      "zh": "3. 穩定 VT 的電擊心律轉復",
      "description": {
        "en": "Preferred over medications in some situations",
        "zh": "某些情況下優於藥物治療"
      },
      "key_points": [
        {
          "en": "Always use SYNCHRONIZED MODE for VT with PULSE",
          "zh": "有脈搏的 VT 必須使用同步模式"
        },
        {
          "en": "SEDATION REQUIRED if patient conscious",
          "zh": "若病患清醒，需先給予鎮靜"
        }
      ]
    },
    "address_reversible_factors": {
      "en": "4. Address Electrolytes and Reversible Factors",
      "zh": "4. 評估電解質與可逆因素",
      "critical_corrections": [
        {
          "factor": "hypokalemia",
          "en": "Hypokalemia: Target K⁺ > 4.0 mEq/L in arrhythmia patients",
          "zh": "低血鉀：心律不整病患目標 K⁺ > 4.0 mEq/L"
        },
        {
          "factor": "hypomagnesemia",
          "en": "Hypomagnesemia: Replete Mg²⁺ (especially important in Torsades)",
          "zh": "低血鎂：補充 Mg²⁺（對 Torsades 尤為重要）"
        },
        {
          "factor": "hypocalcemia",
          "en": "Hypocalcemia: Correct if present",
          "zh": "低血鈣：如有則矯正"
        },
        {
          "factor": "drug_toxicity",
          "en": "Eliminate Drug Toxicity: Discontinue QT-prolonging agents, digoxin if toxic",
          "zh": "排除藥物毒性：停用延長 QT 藥物；若毛地黃中毒則停藥"
        }
      ],
      "drug_selection_considerations": {
        "en": "Drug Selection Considerations",
        "zh": "藥物選擇考量",
        "items": [
          {
            "en": "Amiodarone: First-line, reduced EF",
            "zh": "Amiodarone：第一線，適用於射出分率降低者"
          },
          {
            "en": "Lidocaine: Ischemia/MI setting",
            "zh": "Lidocaine：缺血/心肌梗塞情況"
          },
          {
            "en": "Procainamide: Monitor QRS/BP, avoid in severe HF",
            "zh": "Procainamide：監測 QRS 及血壓，嚴重心衰竭時避免"
          }
        ]
      }
    },
    "pulseless_vt_acls": {
      "en": "Pulseless VT - ACLS Algorithm",
      "zh": "無脈搏 VT — ACLS 流程",
      "pharmacotherapy": {
        "en": "Pharmacotherapy during CPR",
        "zh": "CPR 期間藥物治療",
        "agents": [
          {
            "drug": "Epinephrine",
            "dose": {
              "en": "1 mg IV/IO every 3-5 minutes",
              "zh": "1 mg IV/IO 每 3-5 分鐘"
            }
          },
          {
            "drug": "Amiodarone",
            "dose": {
              "en": "300 mg IV/IO first dose after 2-3 shocks; 150 mg second dose",
              "zh": "首劑 300 mg IV/IO（在 2-3 次電擊後）；第二劑 150 mg"
            }
          },
          {
            "drug": "Lidocaine",
            "dose": {
              "en": "1-1.5 mg/kg first dose; 0.5-0.75 mg/kg subsequent (alternative to amiodarone)",
              "zh": "首劑 1-1.5 mg/kg；後續 0.5-0.75 mg/kg（作為 Amiodarone 的替代選擇）"
            }
          }
        ]
      }
    }
  },
  "prevention": {
    "en": "Long-Term Prevention of Ventricular Tachycardia",
    "zh": "心室頻脈的長期預防",
    "icd": {
      "en": "1. Implantable Cardioverter-Defibrillator (ICD)",
      "zh": "1. 植入式心律去顫器（ICD）",
      "purpose": {
        "en": "Reduce sudden cardiac death risk by providing immediate defibrillation",
        "zh": "提供即時電擊去顫，降低心因性猝死風險"
      },
      "primary_prevention": {
        "en": "Primary Prevention (Heart Failure)",
        "zh": "初級預防（心衰竭）",
        "indications": [
          {
            "en": "EF ≤ 35% with NYHA Class II-III heart failure",
            "zh": "射出分率 ≤ 35% 合併 NYHA II-III 級心衰竭"
          },
          {
            "en": "Prior MI with EF ≤ 30%",
            "zh": "心肌梗塞後射出分率 ≤ 30%"
          },
          {
            "en": "High-risk cardiomyopathy (HCM, ARVC with risk factors)",
            "zh": "高風險心肌病變（HCM、合併危險因子的 ARVC）"
          }
        ]
      },
      "secondary_prevention": {
        "en": "Secondary Prevention (Survivors of VT/VF)",
        "zh": "次級預防（VT/VF 存活者）",
        "indications": [
          {
            "en": "Sustained VT/VF survivors",
            "zh": "持續性 VT/VF 存活者"
          },
          {
            "en": "Not completely reversible cause",
            "zh": "非完全可逆的原因"
          }
        ]
      }
    },
    "antiarrhythmic_drug_therapy": {
      "en": "2. Antiarrhythmic Drug Therapy",
      "zh": "2. 抗心律不整藥物治療",
      "agents": [
        {
          "drug": "Amiodarone",
          "role": {
            "en": "Most effective for reducing VT recurrence",
            "zh": "減少 VT 復發最有效"
          },
          "considerations": {
            "en": "Significant long-term toxicity: thyroid, pulmonary, hepatic",
            "zh": "長期使用有明顯毒性：甲狀腺、肺部、肝臟"
          }
        },
        {
          "drug": "Sotalol",
          "role": {
            "en": "Combined β-blocker and Class III effects",
            "zh": "合併 β 受體阻斷劑及第三類抗心律不整作用"
          },
          "considerations": {
            "en": "Proarrhythmic risk; requires QT monitoring",
            "zh": "有致心律不整風險；需監測 QT"
          }
        },
        {
          "drug": "Beta-blockers",
          "role": {
            "en": "First-line adjunct therapy, reduce sympathetic triggers",
            "zh": "第一線輔助用藥，減少交感神經觸發"
          },
          "considerations": {
            "en": "Mortality benefit in heart failure",
            "zh": "心衰竭病患有死亡率效益"
          }
        },
        {
          "drug": "Mexiletine",
          "role": {
            "en": "Adjunct to amiodarone",
            "zh": "Amiodarone 的輔助用藥"
          },
          "considerations": {
            "en": "Useful in refractory cases",
            "zh": "用於難治性病例"
          }
        }
      ]
    },
    "catheter_ablation": {
      "en": "3. Catheter Ablation",
      "zh": "3. 導管消融術",
      "description": {
        "en": "Highly effective for VT with identifiable foci",
        "zh": "對於具有明確病灶的 VT 療效佳"
      },
      "indications": {
        "en": "Indications for Catheter Ablation",
        "zh": "導管消融術適應症",
        "items": [
          {
            "en": "Scar-related VT with recurrent ICD shocks",
            "zh": "疤痕相關 VT 合併反覆 ICD 電擊"
          },
          {
            "en": "Idiopathic VT as potential cure",
            "zh": "原發性 VT 可作為根治性治療"
          },
          {
            "en": "Drug-refractory VT",
            "zh": "藥物難治性 VT"
          },
          {
            "en": "Incessant VT or VT storm",
            "zh": "持續不斷的 VT 或 VT 風暴"
          }
        ]
      },
    "novel_refractory_management": {
      "en": "4. Novel & Refractory VT Management",
      "zh": "4. 新式療法及難治性 VT 處置",
      "star": {
        "name": {
          "en": "Stereotactic Arrhythmia Radioablation (STAR)",
          "zh": "立體定位心律不整放射消融術（STAR）"
        },
        "description": {
          "en": "Uses focused radiation to ablate arrhythmogenic tissue. Non-invasive approach.",
          "zh": "使用聚焦放射線消融致心律不整組織。非侵入性方法。"
        },
        "indications": [
          {
            "en": "Failed catheter ablation",
            "zh": "導管消融術失敗"
          },
          {
            "en": "Not candidates for invasive procedures",
            "zh": "不適合侵入性手術者"
          }
        ]
      },
      "lcsd": {
        "name": {
          "en": "Left Cardiac Sympathetic Denervation (LCSD)",
          "zh": "左側心臟交感神經切斷術（LCSD）"
        },
        "description": {
          "en": "Surgical denervation of left stellate ganglion.",
          "zh": "外科切斷左側星狀神經節。"
        },
        "indications": [
          {
            "en": "Useful in catecholaminergic VT (CPVT) and refractory VT storm",
            "zh": "適用於兒茶酚胺敏感性 VT（CPVT）及難治性 VT 風暴"
          },
          {
            "en": "Long QT syndrome with recurrent events despite beta-blockers",
            "zh": "長 QT 症候群使用 β 阻斷劑後仍反覆發作者"
          }
        ]
      }
    }
  },
  "special_considerations": {
    "vt_storm": {
      "en": "VT Storm",
      "zh": "VT 風暴",
      "definition": {
        "en": "≥ 3 separate episodes of sustained VT within 24 hours, each requiring intervention",
        "zh": "24 小時內發生 ≥ 3 次獨立的持續性 VT 發作，每次均需介入處理"
      },
      "management": [
        {
          "en": "Aggressive electrolyte correction",
          "zh": "積極矯正電解質"
        },
        {
          "en": "IV amiodarone",
          "zh": "靜脈 Amiodarone"
        },
        {
          "en": "Beta-blocker (esmolol or propranolol IV)",
          "zh": "β 阻斷劑（esmolol 或 propranolol IV）"
        },
        {
          "en": "Deep sedation/intubation if needed",
          "zh": "必要時深度鎮靜/插管"
        },
        {
          "en": "Consider urgent catheter ablation",
          "zh": "考慮緊急導管消融術"
        }
      ]
    },
    "torsades_de_pointes": {
      "en": "Torsades de Pointes Management",
      "zh": "尖端扭轉型心室頻脈處置",
      "key_treatments": [
        {
          "en": "Magnesium sulfate 1-2 g IV (first-line)",
          "zh": "硫酸鎂 1-2 g IV（第一線）"
        },
        {
          "en": "Discontinue QT-prolonging drugs",
          "zh": "停用延長 QT 的藥物"
        },
        {
          "en": "Correct hypokalemia",
          "zh": "矯正低血鉀"
        },
        {
          "en": "Consider overdrive pacing if refractory",
          "zh": "難治者考慮超速起搏"
        },
        {
          "en": "Isoproterenol for pause-dependent Torsades",
          "zh": "暫停依賴型 Torsades 可用 Isoproterenol"
        }
      ],
      "avoid": {
        "en": "AVOID Amiodarone, Sotalol, Procainamide (all prolong QT)",
        "zh": "避免使用 Amiodarone、Sotalol、Procainamide（均會延長 QT）"
      }
    }
  },
  "summary_table": {
    "en": "VT Management Quick Reference",
    "zh": "VT 處置快速參考",
    "scenarios": [
      {
        "scenario": {
          "en": "Pulseless VT",
          "zh": "無脈搏 VT"
        },
        "action": {
          "en": "CPR + Defibrillation (unsynchronized) + Epinephrine + Amiodarone/Lidocaine",
          "zh": "CPR + 電擊去顫（非同步）+ Epinephrine + Amiodarone/Lidocaine"
        }
      },
      {
        "scenario": {
          "en": "Unstable VT with pulse",
          "zh": "不穩定有脈搏 VT"
        },
        "action": {
          "en": "Synchronized cardioversion (sedate if possible)",
          "zh": "同步電擊（可能時先鎮靜）"
        }
      },
      {
        "scenario": {
          "en": "Stable monomorphic VT",
          "zh": "穩定單型性 VT"
        },
        "action": {
          "en": "Antiarrhythmics (Amiodarone, Lidocaine, Procainamide) or elective cardioversion",
          "zh": "抗心律不整藥（Amiodarone、Lidocaine、Procainamide）或擇期電擊轉復"
        }
      },
      {
        "scenario": {
          "en": "Polymorphic VT with normal QT",
          "zh": "正常 QT 的多型性 VT"
        },
        "action": {
          "en": "Treat as ischemia; beta-blockers; consider amiodarone",
          "zh": "當作缺血處理；β 阻斷劑；可考慮 Amiodarone"
        }
      },
      {
        "scenario": {
          "en": "Torsades de Pointes (prolonged QT)",
          "zh": "Torsades de Pointes（QT 延長）"
        },
        "action": {
          "en": "Magnesium IV; stop QT drugs; consider pacing",
          "zh": "硫酸鎂 IV；停用 QT 延長藥物；考慮起搏"
        }
      }
    ]
  }
  },
  "references": {
    "guidelines": [
      "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death",
      "2022 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death",
      "2020 AHA Guidelines for CPR and Emergency Cardiovascular Care",
      "2018 AHA Focused Update on ACLS Use of Antiarrhythmic Drugs",
      "2025 AHA ACLS Guidelines Update"
    ]
  }
}
